Provectus Biopharmaceuticals converts $542,500 in accrued director fees into Series D-1 preferred shares at $2.86 each

PROVECTUS BIOPHARMACEUTICALS INC

PROVECTUS BIOPHARMACEUTICALS INC

PVCT

0.00
  • Provectus Biopharmaceuticals will settle accrued directors’ fees through June 30, 2026 by issuing Series D-1 Preferred Stock.
  • Total accrued fees of $542,500 will convert at $2.86 per preferred share into 189,554 preferred shares.
  • The preferred shares would convert into 1,895,540 common shares.
  • The conversion is intended to satisfy outstanding cash fees owed to current board members.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031379), on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.